Navigation Links
Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Completion of $2,277,000 Equity Financing
Date:9/10/2007

BASKING RIDGE, N.J., Sept. 10 /PRNewswire-FirstCall/ -- Millennium Biotechnologies Group, Inc. (OTC Bulletin Board: MBTG) announced that it raised $2,277,000 through the private placement of its equity securities. These securities have not been registered under the Securities Act of 1933 and may not be offered or sold in the United States absent registration under such Act or an applicable exemption from the registration requirements. Millennium, through its wholly owned subsidiary, Millennium Biotechnologies, Inc., is now positioned to launch products into the P4 Healthcare oncology network and the U.S. and International sports markets.

The recently announced P4 Healthcare relationship is an unprecedented approach to nutrition in the medical markets. Many of the largest private oncology practices in the country will be preferentially offering RESURGEX(R) products to their patients, in their offices, beginning in Q4 of '07. In addition, the Resurgex line of products will be strategically marketed by P4 in its professional Caring4Cancer journal and informative website, http://www.caring4cancer.com

After several successful clinical trials, Millennium will launch its new sports product SURGEX(TM) into the U.S. and International sports markets in Q4 of '07. The response to the results of the trials as well as feedback on SURGEX(TM) from many professional strength and conditioning coaches and players, has been overwhelmingly positive, and sets the stage for a national and international launch.

About Millennium Biotechnologies, Inc.: Millennium Biotechnologies, Inc. is a research-based nutraceutical company and a pioneer in the emerging field of specialized nutritional supplements. The company's flagship products, Resurgex(R), Resurgex Plus(R), and Resurgex Select(R), are designed to assist in reducing fatigue and oxidative stress, maintaining lean muscle and immune support in immunocompromi
'/>"/>

SOURCE Millennium Biotechnologies Group, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. CPM Marketing Group, Announces Alliance for Healthcare Technology
2. Speaker announces business members of IT Task Force
3. Doyle announces technology tax credits for Berbee
4. Doyle announces new energy, global warming policies
5. Doyle announces $80M renewable energy strategy
6. GE announces first installation of Discovery VCT
7. UWM announces winners of RGI awards
8. Third Wave announces two senior management appointments
9. Mirus announces new method for making antibodies
10. Merge announces sofware updates, upcoming acquisition
11. Small Tree announces ethernet solution for Apple Xserv G5

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)..., VIENNA, Austria, November 19 ...gram on one product candidate at an unexpectedly e...D02 is planned to enter into,Phase II clinical tri...ediately follows the completion of two Phase I tri... based its fast decision on the first interim,anal...
(Date:11/18/2009)...t the National Institute of Standards and Technolo...expensive method for detecting and measuring elusi..., invisible spoilage in food or pesticides distrib...d is more sensitive than conventional techniques f...polarlike water molecules, having distinct electri...
(Date:11/18/2009)..., Ill. Imagine a polka-dotted postage stamp that ...ply by changing colors. , As reported in the Sep...neth Suslick and his team at the University of Ill...neral detection of toxic industrial chemicals (TIC... by visualizing odors. This sensor array could be...
(Date:11/18/2009)...ICHMOND, Calif., Nov. 18 ...ced today that data from the University of Pennsyl...of Sangamo,s zinc finger nuclease (ZFN) based prod... prematurely disclosed on the internet. ,, Data...ity of Pennsylvania School of Medicine from a sing...
Breaking Biology Technology:AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 2AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 3Prototype NIST method detects and measures elusive hazards 2Opto-electronic nose sniffs out toxic gases 2Opto-electronic nose sniffs out toxic gases 3Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS 2
.... (Nasdaq: HGSI ) announced today that its presen...erence will be webcast and may be accessed,at htt.../cgi-bin/prnh/20010612/HGSLOGO ), A member of Hu...resent,an overview of the company on Wednesday, Ja... Eastern Time., Investors interested in listening...
...reatment of multi-drug res...b-X Pharmaceuticals, Inc.,("Rib-X" or the "Company...elopment of novel antibiotics for the treatment of...the enrolment of the first patients in two,separat...te the safety and,efficacy of RX-1741 in the treat...
... THRM ), a leader in non-invasive tissue tightenin...it will present at the 10th Annual Needham &,Compa...rk City. The,Company,s presentation is scheduled f...Time. Stephen J. Fanning, Chairman, President and ... business strategy and,historical financial result...
Other Biology Technology:Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741 2Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741 3
(Date:11/20/2009)...009) Scientists from the Marine Biogeochemistry a...search Laboratory (NRL) organized and led a team o...c expedition to initiate methane hydrate explorati...ariation of sediment contribution to Arctic climat...r Polar Sea as a research platform, three cross-sh...
(Date:11/20/2009)...coal-tar-based sealcoats in parking lots may be th... a USGS study. PAHs or polycyclic aromatic hydro...d tar deposits, and can have toxic effects. It,s l...dust; however, the specific sources of these PAHs ...ust from indoor areas near parking lots with coal-...
(Date:11/20/2009)... German . , In the current online issue of ...nie Eyerich and Dr. Kilian Eyerich together with t...stituto Dermopatico dell,Immacolata in Rome, prese... milestone on the way to developing new treatment ...riasis and allergic reactions and potentially also...
Breaking Biology News(10 mins):International expedition investigates climate change, alternative fuels in Arctic 2From toxic dust and algae to ill winds from Africa 2From toxic dust and algae to ill winds from Africa 3From toxic dust and algae to ill winds from Africa 4From toxic dust and algae to ill winds from Africa 5Discovery of new type of immune cells regulating inflammation in chronic diseases 2Novavax Launches Pivotal Clinical Study of Novel 2009 H1N1 VLP Flu Vaccine in Mexico 5583 1Novavax Launches Pivotal Clinical Study of Novel 2009 H1N1 VLP Flu Vaccine in Mexico 5583 2Novavax Launches Pivotal Clinical Study of Novel 2009 H1N1 VLP Flu Vaccine in Mexico 5583 3Novavax Launches Pivotal Clinical Study of Novel 2009 H1N1 VLP Flu Vaccine in Mexico 5583 4Novavax Launches Pivotal Clinical Study of Novel 2009 H1N1 VLP Flu Vaccine in Mexico 5583 5The Growing Demand for Organic Gardening Sprouts New Self Sustaining Innovations 14535 1The Growing Demand for Organic Gardening Sprouts New Self Sustaining Innovations 14535 2The Growing Demand for Organic Gardening Sprouts New Self Sustaining Innovations 14535 3Vascular Study Group of New England Selects Clinical Data Pathways Powered by M2S as Quality Improvement Registry Provider 59791 1Vascular Study Group of New England Selects Clinical Data Pathways Powered by M2S as Quality Improvement Registry Provider 59791 2Vascular Study Group of New England Selects Clinical Data Pathways Powered by M2S as Quality Improvement Registry Provider 59791 3
... to indicate that the diversity of marine creature...s of years in step with predator-prey encounters, ...ngs of the National Academy of Science. , For dec...sts, biologists, and ecologists on the role of eco...ng term patterns of animal evolution. , John War...
...tant to UNESCO and a former Administrator of the N...AA), will deliver a talk at Stevens Institute of T...e Habitability of Planet Earth: A Time of Reckonin... Center for Technology Management, Room 122, at 3:... the Stevens campus in Hoboken, N.J., near the int...
...harmaceuticals (NASDAQ: ABPI) announces evidence t...S), are due to a fungal-induced inflammation as or...nic. The data were collected as part of the Compa... lead pharmaceutical product, SinuNase, an intrana....01% suspension. In order to be enrolled in the c...
Other Biology News:Study reveals predation-evolution link 2Study reveals predation-evolution link 3Global Warming and the Habitability of Planet Earth, Sept. 26 2SinuNase Phase 3 show almost 100 percent of chronic sinusitis cases are from fungal-induced inflamma 2
Rabbit anti-QKI AbVantage Pack Polyclonal Antibody, Unconjugated from Bethyl Laboratories
Direct ELISA Assay Diluent from BioFX Laboratories, Inc.
Assay Diluent from BioFX Laboratories, Inc.
Assay Diluent Trial Pack from BioFX Laboratories, Inc.
Biology Products: